<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Clinical Medicine</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/F4C69DB3-E990-4DDD-BCA3-CED9FFBA40A9"><gtr:id>F4C69DB3-E990-4DDD-BCA3-CED9FFBA40A9</gtr:id><gtr:firstName>Louise</gtr:firstName><gtr:otherNames>Anne</gtr:otherNames><gtr:surname>Johnson</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0801186"><gtr:id>364701B6-D05D-4624-9B82-1D58DAADF673</gtr:id><gtr:title>Molecular Regulation of leukocyte trafficking into and through the afferent lymphatics</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0801186</gtr:grantReference><gtr:abstractText>The ability of an animal or human to fight infection is dependent upon the generation of an immune response to foreign material, termed antigen, such as bacteria or viruses. However, under some circumstances, an immune response is either inappropriate or not in the best interest of the individual, for example following an organ transplant or skin graft. Current immune suppression therapies have unwanted side-effects of preventing immune responses throughout the body. Therefore future therapies to avert only local immune responses, whilst leaving the rest of the body protected, would be advantageous.
 The research outlined in this proposal would examine the first stage in the generation of an immune response, where antigen-presenting immune cells (having acquired foreign material) must enter the lymphatic system to migrate to the draining lymph node, to activate other immune cells and instigate a specific, targeted response to the antigen. My research to date has shown that this passage of immune cells into the lymphatics is carefully regulated by lymphatic-expressed adhesion molecules binding to corresponding receptors on the immune cell. Blocking these interactions impairs adhesion to and transmigration into the lymphatics, thus impeding migration of the immune cell to the lymph node and reducing the immune response to antigen. I now seek funding to elucidate the broader cascade of adhesion events, other adhesion and cell-junctional molecules involved and the effect of blocking them in vitro and in mouse models of inflammation and skin graft rejection. This research has the potential to identify important new targets for preventing transplant rejection whilst avoiding systemic immune suppression, as well as improving our understanding of the mechanisms and regulation of immune surveillance.</gtr:abstractText><gtr:technicalSummary>Primary immune responses to foreign antigen from the periphery are initiated within the lymph nodes and are dependent upon efficient delivery of antigen by antigen-presenting cells such as dendritic cells (DCs) in the skin dermis. The majority of DCs do not circulate in the blood; rather they are inherent in the tissues and therefore traffic to lymph node via the afferent lymphatics. Other leukocyte populations found in the afferent lymphatics include monocytes, T cells, macrophages and neutrophils. My research to date has shown that passage of leukocytes into the afferent lymphatics is carefully regulated by lymphatic endothelial-expressed adhesion molecules ICAM-1 and VCAM-1 and blocking the binding of these to their cognate integrin ligands impairs trafficking of APCs to the lymph node and CD8+ T-cell response to viral antigen. I now seek funding to elucidate the cascade of adhesion events, other adhesion and junction molecules involved and the effect of neutralising them in vitro and in vivo.</gtr:technicalSummary><gtr:fund><gtr:end>2011-11-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-12-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>278382</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Previously, a LYVE1 deficient mouse existed but was on a C57Bl6 background and no phenotype was identified. As LYVE1 is implicated in numerous physiological processes, it was considered possible (as has been the case with other genes) that a deficiency on another background may result in a more apparent phenotype.</gtr:description><gtr:id>B1D80FC2-47E1-45A7-B145-8A2EF5639B28</gtr:id><gtr:impact>I have found that LYVE-1 knock-out mice on the newly derived BALB/c background have a defect in dendritic cell trafficking. I am currently carrying out more experiments to characterise this and will be submitting the findings to a high-impact journal in the next three months.</gtr:impact><gtr:outcomeId>rRLAFcLFnhH</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Breeding a LYVE1 knock-out mouse on a BALB/c background</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>I visited another laboratory and learned their methods of intravital microscopy, adapting these methods to examine dendritic cell trafficking into and through afferent lymphatic vessels.</gtr:description><gtr:id>DD35005F-38C4-4A46-B6C5-41377F061E06</gtr:id><gtr:impact>These techniques have previously not been used in the Institute where I currently work and will allow me (and other researchers) to examine the early stages in development of an immune response and the molecular and cellular mechanisms involved.</gtr:impact><gtr:outcomeId>hahvUUEvJMY</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Intravital microscopy of trafficking into afferent lymphatics</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>1407E44E-B852-4563-AF0D-43B11E98F40D</gtr:id><gtr:title>Renal cells activate the platelet receptor CLEC-2 through podoplanin.</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7dfa75813aa9e1324ba03e32c545cbd7"><gtr:id>7dfa75813aa9e1324ba03e32c545cbd7</gtr:id><gtr:otherNames>Christou CM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn><gtr:outcomeId>csgB7PqM3Te</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1EBF6C0B-8556-4AEB-A194-B9BC409E6A9D</gtr:id><gtr:title>Cell traffic and the lymphatic endothelium.</gtr:title><gtr:parentPublicationTitle>Annals of the New York Academy of Sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4045ec99722c5d534bac690f76cfe482"><gtr:id>4045ec99722c5d534bac690f76cfe482</gtr:id><gtr:otherNames>Johnson LA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0077-8923</gtr:issn><gtr:outcomeId>QqbiRFceDhS</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>12AF263C-56CD-4149-88B5-D1466599A478</gtr:id><gtr:title>An inflammation-induced mechanism for leukocyte transmigration across lymphatic vessel endothelium.</gtr:title><gtr:parentPublicationTitle>The Journal of experimental medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4045ec99722c5d534bac690f76cfe482"><gtr:id>4045ec99722c5d534bac690f76cfe482</gtr:id><gtr:otherNames>Johnson LA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0022-1007</gtr:issn><gtr:outcomeId>qYMARHKK3p9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>81C0460E-0B3E-491F-A3FE-BE40829E65D9</gtr:id><gtr:title>Inflammation-induced uptake and degradation of the lymphatic endothelial hyaluronan receptor LYVE-1.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4045ec99722c5d534bac690f76cfe482"><gtr:id>4045ec99722c5d534bac690f76cfe482</gtr:id><gtr:otherNames>Johnson LA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>djoi12LnqpT</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>994429F0-1382-4DC8-B092-BAF8DE4440E1</gtr:id><gtr:title>Inflammation-induced secretion of CCL21 in lymphatic endothelium is a key regulator of integrin-mediated dendritic cell transmigration.</gtr:title><gtr:parentPublicationTitle>International immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4045ec99722c5d534bac690f76cfe482"><gtr:id>4045ec99722c5d534bac690f76cfe482</gtr:id><gtr:otherNames>Johnson LA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0953-8178</gtr:issn><gtr:outcomeId>KpVbeNkYdqN</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FAD27BF7-E718-4D6A-A336-FBE848123298</gtr:id><gtr:title>Blocking development of a CD8+ T cell response by targeting lymphatic recruitment of APC.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0c5a9c8be01312f74038c2cc7616212f"><gtr:id>0c5a9c8be01312f74038c2cc7616212f</gtr:id><gtr:otherNames>Teoh D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>SynZVqbWWEc</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0801186</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>